Literature DB >> 18040708

Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis.

Alfonso Iovieno1, Alessandro Lambiase, Marta Sacchetti, Barbara Stampachiacchiere, Alessandra Micera, Stefano Bonini.   

Abstract

BACKGROUND: Probiotics have been shown to improve allergic inflammation. The aim of this study was to evaluate the efficacy of Lactobacillus Acidophilus eye-drops in controlling signs and symptoms of vernal keratoconjunctivitis (VKC).
METHODS: Seven patients (mean age 11.8 +/- 4.3; five M, two F) with mild to moderate VKC were included in the study. Lactobacillus Acidophilus diluted in saline solution (2 x 10(8) CFU/ml) was administrated as eye-drops four times daily for 4 weeks in both eyes. Clinical signs (conjunctival hyperemia, chemosis, secretion, Trantas dots, superficial punctuate keratitis) and symptoms (itching, photophobia, burning, tearing) were evaluated and scored from 0 to 3 at baseline, after 2 and 4 weeks of treatment. Total sign (TSS) and symptom (TSyS) scores were calculated. Conjunctival impression cytology was performed in three patients at baseline and after 4 weeks of treatment, in order to evaluate the expression of ICAM-1 and TLR-4.
RESULTS: In the six out of seven patients who completed the study, symptoms were significantly improved after both 2 weeks (TSyS: baseline 6.7 +/- 0.9 vs 4.1 +/- 1.2; p = 0.017) and 4 weeks (TSyS: baseline 6.7 +/- 0.9 vs 3.6 +/- 1.2, p = 0.011) of treatment. A significant improvement of clinical signs was observed after 4 weeks of treatment (TSS: baseline 7.5 +/- 1.6 vs 3.9 +/- 1.7, p = 0.034) but not after 2 weeks of treatment (TSS: baseline 7.5 +/- 1.6 vs 5.3 +/- 1.5; NS). In particular, photophobia was significantly reduced (2 +/- 0.6 vs 1 +/- 0.3; p = 0.023) at 2 weeks, while at 4 weeks the scores for itching (1.8 +/- 0.3 vs 1 +/- 0.3), tearing (1.6 +/- 0.4 vs 0.8 +/- 0.2), conjunctival hyperemia (2.3 +/- 0.2 vs 1.4 +/- 0.5) and chemosis (1.2 +/- 0.4 vs 0.4 +/- 0.4) were significantly lower compared to baseline. A down-regulation of ICAM-1 and TLR-4 was observed in two patients showing clinical improvement after 4 weeks of treatment.
CONCLUSION: Our open pilot study showed that 1-month treatment with probiotic eye-drops improves signs and symptoms in patients with VKC. Additional double-blind controlled clinical trials with a larger sample of patients are needed to confirm the effects of topical Lactobacilli on VKC patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040708     DOI: 10.1007/s00417-007-0682-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  30 in total

Review 1.  Microbial products in allergy prevention and therapy.

Authors:  P M Matricardi; B Bjorksten; S Bonini; J Bousquet; R Djukanovic; S Dreborg; J Gereda; H-J Malling; T Popov; E Raz; H Renz; A Wold
Journal:  Allergy       Date:  2003-06       Impact factor: 13.146

2.  Hay fever, hygiene, and household size.

Authors:  D P Strachan
Journal:  BMJ       Date:  1989-11-18

3.  Effects of specific lactic acid bacteria on the intestinal permeability to macromolecules and the inflammatory condition.

Authors:  Martine Heyman; Kathleen Terpend; Sandrine Ménard
Journal:  Acta Paediatr Suppl       Date:  2005-10

4.  Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction.

Authors:  A Ait-Belgnaoui; W Han; F Lamine; H Eutamene; J Fioramonti; L Bueno; V Theodorou
Journal:  Gut       Date:  2006-02-28       Impact factor: 23.059

5.  Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial.

Authors:  M Kalliomäki; S Salminen; H Arvilommi; P Kero; P Koskinen; E Isolauri
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

Review 6.  The role of probiotics in the management of allergic disease.

Authors:  R J Boyle; M L K Tang
Journal:  Clin Exp Allergy       Date:  2006-05       Impact factor: 5.018

7.  Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells.

Authors:  M Miettinen; S Matikainen; J Vuopio-Varkila; J Pirhonen; K Varkila; M Kurimoto; I Julkunen
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial.

Authors:  Marko Kalliomäki; Seppo Salminen; Tuija Poussa; Heikki Arvilommi; Erika Isolauri
Journal:  Lancet       Date:  2003-05-31       Impact factor: 79.321

9.  Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function.

Authors:  Yukiko I Nigo; Masakatsu Yamashita; Kiyoshi Hirahara; Ryo Shinnakasu; Masamichi Inami; Motoko Kimura; Akihiro Hasegawa; Yoichi Kohno; Toshinori Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

Review 10.  Vernal keratoconjunctivitis.

Authors:  S Bonini; M Coassin; S Aronni; A Lambiase
Journal:  Eye (Lond)       Date:  2004-04       Impact factor: 3.775

View more
  19 in total

Review 1.  [Pre- and probiotic cosmetics].

Authors:  R Simmering; R Breves
Journal:  Hautarzt       Date:  2009-10       Impact factor: 0.751

2.  Intestinal microbiome: a new target for chalaziosis treatment in children?

Authors:  Mariaelena Filippelli; Roberto dell'Omo; Angela Amoruso; Ilaria Paiano; Marco Pane; Pasquale Napolitano; Silvia Bartollino; Ciro Costagliola
Journal:  Eur J Pediatr       Date:  2020-11-23       Impact factor: 3.183

Review 3.  The microbiome and ophthalmic disease.

Authors:  Adam D Baim; Asadolah Movahedan; Asim V Farooq; Dimitra Skondra
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-21

4.  Effectiveness of oral probiotics supplementation in the treatment of adult small chalazion.

Authors:  Mariaelena Filippelli; Roberto dell'Omo; Angela Amoruso; Ilaria Paiano; Marco Pane; Pasquale Napolitano; Giuseppe Campagna; Silvia Bartollino; Ciro Costagliola
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

5.  Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells.

Authors:  Alessandra Micera; Barbara Stampachiacchiere; Eduardo Maria Normando; Alessandro Lambiase; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2009-10-13       Impact factor: 2.367

6.  A Probiotic Adjuvant Lactobacillus rhamnosus Enhances Specific Immune Responses after Ocular Mucosal Immunization with Chlamydial Polymorphic Membrane Protein C.

Authors:  Aleksandra Inic-Kanada; Marijana Stojanovic; Emilija Marinkovic; Elisabeth Becker; Elisabeth Stein; Ivana Lukic; Radmila Djokic; Nadine Schuerer; Johannes H Hegemann; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

7.  Ocular Surface Microbiome Alterations Are Found in Both Eyes of Individuals With Unilateral Infectious Keratitis.

Authors:  Kara M Cavuoto; Anat Galor; Santanu Banerjee
Journal:  Transl Vis Sci Technol       Date:  2021-02-05       Impact factor: 3.283

8.  Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.

Authors:  Jacqueline Montanaro; Aleksandra Inic-Kanada; Angela Ladurner; Elisabeth Stein; Sandra Belij; Nora Bintner; Simone Schlacher; Nadine Schuerer; Ulrike Beate Mayr; Werner Lubitz; Nikolaus Leisch; Talin Barisani-Asenbauer
Journal:  Drug Des Devel Ther       Date:  2015-07-21       Impact factor: 4.162

9.  The closed eye harbours a unique microbiome in dry eye disease.

Authors:  Kent A Willis; Cameron K Postnikoff; Amelia Freeman; Gabriel Rezonzew; Kelly Nichols; Amit Gaggar; Charitharth V Lal
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

Review 10.  Influence of gut microbiota on eye diseases: an overview.

Authors:  Pasquale Napolitano; Mariaelena Filippelli; Sergio Davinelli; Silvia Bartollino; Roberto dell'Omo; Ciro Costagliola
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.